Published in Ann Rheum Dis on November 15, 2006
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum (2010) 4.57
CD40 and autoimmunity: the dark side of a great activator. Semin Immunol (2009) 1.80
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther (2011) 1.53
Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol (2009) 1.49
Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol (2010) 1.40
B-cell-depletion therapy in SLE--what are the current prospects for its acceptance? Nat Rev Rheumatol (2009) 1.35
Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis (2009) 1.27
Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther (2009) 1.27
Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res (2009) 1.24
Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy. Clin Exp Immunol (2009) 1.23
Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol (2010) 1.21
Effect of B-cell depletion on viral replication and clinical outcome of simian immunodeficiency virus infection in a natural host. J Virol (2009) 1.09
Neuropsychiatric systemic lupus erythematosus. Curr Neuropharmacol (2011) 1.04
Minimal change disease: a "two-hit" podocyte immune disorder? Pediatr Nephrol (2010) 1.04
Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum (2008) 1.01
B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther (2013) 0.99
The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int (2007) 0.98
Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front Cell Neurosci (2015) 0.96
Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther (2008) 0.95
Central nervous system vasculitis: still more questions than answers. Curr Neuropharmacol (2011) 0.90
Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies. Clin Exp Immunol (2012) 0.89
Temporal requirements for B cells in the establishment of CD4 T cell memory. J Immunol (2013) 0.89
Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. Drugs (2016) 0.88
Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning? Discov Med (2010) 0.87
Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. J Biomed Biotechnol (2010) 0.85
Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus. J Clin Immunol (2009) 0.83
Effects of adjuvants for human use in systemic lupus erythematosus (SLE)-prone (New Zealand black/New Zealand white) F1 mice. Clin Exp Immunol (2014) 0.82
Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis. J Zhejiang Univ Sci B (2012) 0.82
SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis (2011) 0.80
B cell and/or autoantibody deficiency do not prevent neuropsychiatric disease in murine systemic lupus erythematosus. J Neuroinflammation (2016) 0.77
Contemporary treatment of systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis (2010) 0.76
Neuropsychiatric lupus. Sultan Qaboos Univ Med J (2013) 0.76
Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord (2016) 0.75
Psychosis in a young female - a diagnostic and therapeutic challenge. JRSM Short Rep (2010) 0.75
Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study. Clin Exp Immunol (2013) 0.75
Cranial nerve palsies: sarcoidosis to systemic lupus erythematosus. Case Rep Rheumatol (2013) 0.75
Parkinsonism can be cured. BMJ Case Rep (2013) 0.75
Two negative randomized controlled trials in lupus: now what? F1000 Med Rep (2009) 0.75
The role of B cells and autoantibodies in neuropsychiatric lupus. Autoimmun Rev (2016) 0.75
A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study. Arthritis Res Ther (2016) 0.75
Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome. Biomed Rep (2016) 0.75
B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab. Biologics (2012) 0.75
Rituximab in the treatment of severe lupus myelopathy. Clin Rheumatol (2011) 0.75
Severe neuropsychiatric systemic lupus erythematosus successfully treated with rituximab: an alternative to standard of care. Open Access Rheumatol (2017) 0.75
Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther (2017) 0.75
[Established medications : new areas of application]. Z Rheumatol (2013) 0.75
[Diagnosis and therapy of neurological manifestations of inflammatory rheumatic diseases]. Z Rheumatol (2008) 0.75
The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1982) 67.54
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum (1999) 7.30
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 6.47
B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum (2004) 3.35
Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum (2005) 3.25
Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med (2005) 3.04
Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum (2005) 2.55
An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum (2002) 2.54
Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum (2004) 2.23
Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) (2004) 2.19
Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum (2005) 2.01
Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest (1996) 1.86
B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) (2005) 1.83
Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients. Clin Immunol Immunopathol (1997) 1.75
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis (2002) 1.74
Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum (2004) 1.66
Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report. Pediatr Nephrol (2005) 1.55
Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis (2005) 1.51
Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol (2002) 1.15
Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis (2001) 1.14
Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus (2003) 1.08
Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus (2004) 1.05
CD40-CD40 ligand interaction in autoimmune disease. Arthritis Rheum (1997) 1.03
Neuropsychiatric features of systemic lupus erythematosus. Autoimmun Rev (2005) 0.98
Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin Rheumatol (1999) 0.96
Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med (1991) 0.94
New therapies for systemic lupus erythematosus. Clin Exp Immunol (2005) 0.92
Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate. Springer Semin Immunopathol (1994) 0.90
Survival analysis of 306 European Spanish patients with systemic lupus erythematosus. Lupus (1998) 0.90
Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: report of a consensus meeting. Arthritis Rheum (2004) 0.89
Elevated in vivo expression of the costimulatory molecule B7-BB1 (CD80) on antigen presenting cells from a patient with SLE. Clin Exp Rheumatol (1997) 0.86
Causes of death and prognostic factors in Thai patients with systemic lupus erythematosus. Asian Pac J Allergy Immunol (2002) 0.86
T cells in the pathogenesis of systemic lupus erythematosus: potential roles of CD154-CD40 interactions and costimulatory molecules. Curr Rheumatol Rep (2000) 0.84
SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody). Rheumatol Int (2005) 0.84
Simultaneous determination of cerebrospinal fluid oligoclonal bands and the "gamma-protein index" by agarose electrophoresis and densitometry. Clin Chem (1986) 0.78
[The expression and significance of costimulatory molecule in peripheral blood B lymphocytes in rheumatoid arthritis]. Zhonghua Nei Ke Za Zhi (2004) 0.78
Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol (2012) 7.39
A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol (2011) 4.26
Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol (2010) 2.53
STATs shape the active enhancer landscape of T cell populations. Cell (2012) 2.45
TGF-β and retinoic acid induce the microRNA miR-10a, which targets Bcl-6 and constrains the plasticity of helper T cells. Nat Immunol (2012) 2.37
A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat Genet (2010) 2.34
Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. Nat Genet (2012) 2.31
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum (2013) 2.13
Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum (2005) 2.11
Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci U S A (2011) 1.80
Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis. Arthritis Rheum (2009) 1.69
Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab. J Rheumatol (2010) 1.67
Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis (2013) 1.64
Complement drives Th17 cell differentiation and triggers autoimmune arthritis. J Exp Med (2010) 1.62
The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) (2009) 1.62
Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet (2013) 1.54
Long-term clinical course of a patient with anti PL-12 antibody accompanied by interstitial pneumonia and severe pulmonary hypertension. Intern Med (2005) 1.52
Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) (2010) 1.49
Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody. Endocr J (2008) 1.48
Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis. J Exp Med (2005) 1.46
Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Res Ther (2009) 1.45
Pneumoperitoneum without perforation of the gastrointestinal tract. Dig Surg (2003) 1.42
Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol (2007) 1.41
Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol (2009) 1.39
A novel apoptosis-inducing monoclonal antibody (anti-LHK) against a cell surface antigen on colon cancer cells. J Gastroenterol (2005) 1.39
Adult-onset idiopathic progressive acro-osteolysis with proximal symphalangism. J Bone Miner Res (2004) 1.37
Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol (2008) 1.34
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis (2012) 1.33
Ameliorative effects of follistatin-related protein/TSC-36/FSTL1 on joint inflammation in a mouse model of arthritis. Arthritis Rheum (2004) 1.32
Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy (2005) 1.31
Randomized study of the benefits of preoperative corticosteroid administration on the postoperative morbidity and cytokine response in patients undergoing surgery for esophageal cancer. Ann Surg (2002) 1.31
Laparoscopic paracecal hernia repair. J Laparoendosc Adv Surg Tech A (2003) 1.29
Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Mod Rheumatol (2008) 1.29
Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis (2011) 1.27
Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity (2006) 1.27
Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol (2007) 1.25
Intussusception in adults: a 21-year experience in the university-affiliated emergency center and indication for nonoperative reduction. Dig Surg (2003) 1.22
Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study. Rheumatology (Oxford) (2011) 1.21
Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res (2009) 1.21
Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Ann Rheum Dis (2013) 1.20
The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells. Arthritis Rheum (2011) 1.20
Interleukin-1β induces differentiation of human mesenchymal stem cells into osteoblasts via the Wnt-5a/receptor tyrosine kinase-like orphan receptor 2 pathway. Arthritis Rheum (2012) 1.19
Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol (2013) 1.18
A genome-wide association study identified AFF1 as a susceptibility locus for systemic lupus eyrthematosus in Japanese. PLoS Genet (2012) 1.17
Autocrine induction of the human pro-IL-1beta gene promoter by IL-1beta in monocytes. J Immunol (2002) 1.17
The human AIRE gene at chromosome 21q22 is a genetic determinant for the predisposition to rheumatoid arthritis in Japanese population. Hum Mol Genet (2011) 1.16
Neutrophils are essential as a source of IL-17 in the effector phase of arthritis. PLoS One (2013) 1.15
Anammox organism KSU-1 expresses a NirK-type copper-containing nitrite reductase instead of a NirS-type with cytochrome cd1. FEBS Lett (2012) 1.14
Isolation of a multiheme protein with features of a hydrazine-oxidizing enzyme from an anaerobic ammonium-oxidizing enrichment culture. Appl Environ Microbiol (2006) 1.13
Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol (2009) 1.13
Association of Takayasu arteritis with HLA-B 67:01 and two amino acids in HLA-B protein. Rheumatology (Oxford) (2013) 1.12
Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease. Mod Rheumatol (2010) 1.11
Low prevalence of anti-DFS70/LEDGF antibodies in patients with dermatomyositis and other systemic autoimmune rheumatic diseases. J Rheumatol (2013) 1.11
Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase. J Biol Chem (2008) 1.11
Anti-citrullinated peptide antibody-negative RA is a genetically distinct subset: a definitive study using only bone-erosive ACPA-negative rheumatoid arthritis. Rheumatology (Oxford) (2010) 1.10